<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03288831</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 17-003596</org_study_id>
    <nct_id>NCT03288831</nct_id>
  </id_info>
  <brief_title>Changes in Intestinal Permeability 4 Hours After Gluten Challenge</brief_title>
  <official_title>The Innate Response to and Changes in Intestinal Permeability 4 Hours After a Gluten Challenge in Subjects With Celiac Disease and Non Celiac Gluten Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates why people with celiac disease and non-celiac gluten/wheat sensitivity&#xD;
      develop rapid onset symptoms within hours of gluten exposure. Half of subjects will be given&#xD;
      gluten and half will not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When a person with celiac disease is exposed to gluten, their immune system attacks their&#xD;
      bowel and causes abdominal pain, bloating, and diarrhea. This process takes 24-72 hours to&#xD;
      occur. Some people without celiac disease develop similar symptoms when they eat gluten or&#xD;
      wheat. Doctors and scientists do not know what causes this sensitivity to gluten. People with&#xD;
      celiac disease and non-celiac gluten sensitivity report symptoms within hours of being&#xD;
      exposed to gluten. This study evaluates why this occurs by looking at changes in blood,&#xD;
      urine, stool, and the bowel after being given gluten.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Actual">October 30, 2018</completion_date>
  <primary_completion_date type="Actual">October 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blinded, placebo-controlled oral gluten challenge</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Subjects will be block randomized to either gluten-containing or placebo challenge.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Activation of the Mucosal Innate Immune System after Oral Gluten Challenge</measure>
    <time_frame>4 hours</time_frame>
    <description>Small bowel biopsies will be assessed for markers of innate immune system activation: presence of granulocytes, granulocyte degranulation, products of degranulation, interleukins and cytokines involved in the innate immune system response, inflammatory mediators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Mucosal Permeability after Oral Gluten Challenge</measure>
    <time_frame>Baseline and up to eight hours after gluten or placebo exposure</time_frame>
    <description>Mucosal permeability will be measure before and after oral gluten or placebo challenge with C13-mannitol lactulose urinary excretion testing. In addition, mucosal permeability will also be measured along the duodenum with a mucosal impedance probe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of Gluten Peptides in Urine and Stool</measure>
    <time_frame>Baseline and up to 72 hours after gluten or placebo exposure</time_frame>
    <description>Urine and stool samples will be assessed for the presence of gluten peptides. This will help assess how long these tests are positive after a known gluten exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid Onset Symptom Development after Gluten Exposure</measure>
    <time_frame>Baseline and up to 72 hours after gluten or placebo exposure</time_frame>
    <description>Subjects will record the symptoms they experience after gluten or placebo exposure. The will complete a simple symptom diary every 30 minutes for the first 2 hours.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Celiac Disease</condition>
  <condition>Wheat Hypersensitivity</condition>
  <condition>Gluten Sensitivity</condition>
  <condition>Gluten Enteropathy</condition>
  <condition>Immune System and Related Disorders</condition>
  <condition>Duodenal Diseases</condition>
  <arm_group>
    <arm_group_label>Normal Subjects, Gluten Drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal subjects will drink a solution containing 6 grams of gluten one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Subjects, Placebo Drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal subjects will drink a solution without gluten one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac Subjects, Gluten Drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac Subjects, Placebo Drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with celiac disease will drink a solution without gluten one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gluten Sensitivity, Gluten Drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gluten Sensitivity, Placebo Drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gluten</intervention_name>
    <description>Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.</description>
    <arm_group_label>Celiac Subjects, Gluten Drink</arm_group_label>
    <arm_group_label>Gluten Sensitivity, Gluten Drink</arm_group_label>
    <arm_group_label>Normal Subjects, Gluten Drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will drink a mixture of rice water and Tang flavoring one time.</description>
    <arm_group_label>Celiac Subjects, Placebo Drink</arm_group_label>
    <arm_group_label>Gluten Sensitivity, Placebo Drink</arm_group_label>
    <arm_group_label>Normal Subjects, Placebo Drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects with Celiac Disease:&#xD;
&#xD;
          -  Biopsy proven celiac disease diagnosed at least 2 years prior to recruitment&#xD;
&#xD;
          -  Attest to following a gluten free diet to the best of their ability&#xD;
&#xD;
          -  Quiescent symptoms on a gluten free diet&#xD;
&#xD;
          -  Negative tissue transglutaminase at time of recruitment (to be collected with baseline&#xD;
             blood work)&#xD;
&#xD;
          -  A prior endoscopy with small bowel biopsies reviewed by a gastrointestinal pathologist&#xD;
             revealing healing&#xD;
&#xD;
        Inclusion Criteria for subjects with Non-Celiac Gluten Sensitivity:&#xD;
&#xD;
          -  Meet diagnostic consensus criteria as defined by Ludvigsson et al in &quot;The Oslo&#xD;
             definitions for coeliac disease and related terms&quot;&#xD;
&#xD;
          -  Attest to following a gluten free diet to the best of their ability&#xD;
&#xD;
          -  Quiescent symptoms on a gluten free diet&#xD;
&#xD;
          -  Prior negative evaluation for celiac disease (including tissue transglutaminase IgA&#xD;
             with total IgA or small bowel biopsies)&#xD;
&#xD;
          -  If subjects have had a small bowel biopsies revealing increased intraepithelial&#xD;
             lymphocytes (IELs), they will be reviewed as a separate subgroup&#xD;
&#xD;
        Inclusion Criteria for Normal Subjects:&#xD;
&#xD;
          -  No gastrointestinal diagnosis (reflux, eosinophilic esophagitis, inflammatory bowel&#xD;
             disease, or irritable bowel syndrome)&#xD;
&#xD;
          -  No gastrointestinal symptoms (diarrhea, abdominal pain, nausea, vomiting, weight loss)&#xD;
&#xD;
          -  No family history of celiac disease&#xD;
&#xD;
          -  Will not be required to have a baseline biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tobacco use&#xD;
&#xD;
          -  Symptomatic coronary disease&#xD;
&#xD;
          -  Active, severe pulmonary disease&#xD;
&#xD;
          -  Baseline oxygen requirement&#xD;
&#xD;
          -  Coagulopathy (INR&gt;1.5)&#xD;
&#xD;
          -  Mastocytosis&#xD;
&#xD;
          -  Active H. pylori infection&#xD;
&#xD;
          -  Treated celiac disease with neutrophilia or eosinophilia secondary to infection&#xD;
&#xD;
          -  Diabetes (type 1 and type 2)&#xD;
&#xD;
          -  Crohn's disease or Ulcerative colitis&#xD;
&#xD;
          -  Microscopic colitis&#xD;
&#xD;
          -  Dermatitis herpetiformis&#xD;
&#xD;
          -  Gastroparesis&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
        Subjects exposed to the following medications during their respective time frames will be&#xD;
        excluded:&#xD;
&#xD;
          -  NSAIDs (24 hours)&#xD;
&#xD;
          -  Leukotriene inhibitors (24 hours)&#xD;
&#xD;
          -  Mast cell stabilizers (24 hours)&#xD;
&#xD;
          -  Benzodiazepines (24 hours)&#xD;
&#xD;
          -  H2 blockers (2 days)&#xD;
&#xD;
          -  H1 blockers (7 days)&#xD;
&#xD;
          -  Steroids (systemic or topically active within gastrointestinal tract) (30 days)&#xD;
&#xD;
          -  Topical steroids (14 days)&#xD;
&#xD;
          -  Intermittent (up to once weekly) tranquilizer (trazodone, doxepin) use (7 days)&#xD;
&#xD;
          -  Chronic tricyclic antidepressant or tranquilizer use (trazodone, doxepin) Use of these&#xD;
             medications will also be prohibited during the study duration (AAAAI and AAOA).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A. Murray, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Leffler D, Schuppan D, Pallav K, Najarian R, Goldsmith JD, Hansen J, Kabbani T, Dennis M, Kelly CP. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. 2013 Jul;62(7):996-1004. doi: 10.1136/gutjnl-2012-302196. Epub 2012 May 22.</citation>
    <PMID>22619366</PMID>
  </reference>
  <reference>
    <citation>Adriaanse MP, Tack GJ, Passos VL, Damoiseaux JG, Schreurs MW, van Wijck K, Riedl RG, Masclee AA, Buurman WA, Mulder CJ, Vreugdenhil AC. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013 Feb;37(4):482-90. doi: 10.1111/apt.12194. Epub 2013 Jan 7.</citation>
    <PMID>23289539</PMID>
  </reference>
  <reference>
    <citation>Anderson RP, van Heel DA, Tye-Din JA, Barnardo M, Salio M, Jewell DP, Hill AV. T cells in peripheral blood after gluten challenge in coeliac disease. Gut. 2005 Sep;54(9):1217-23. doi: 10.1136/gut.2004.059998.</citation>
    <PMID>16099789</PMID>
  </reference>
  <reference>
    <citation>Camarca A, Radano G, Di Mase R, Terrone G, Maurano F, Auricchio S, Troncone R, Greco L, Gianfrani C. Short wheat challenge is a reproducible in-vivo assay to detect immune response to gluten. Clin Exp Immunol. 2012 Aug;169(2):129-36. doi: 10.1111/j.1365-2249.2012.04597.x.</citation>
    <PMID>22774987</PMID>
  </reference>
  <reference>
    <citation>Beitnes AC, Raki M, Brottveit M, Lundin KE, Jahnsen FL, Sollid LM. Rapid accumulation of CD14+CD11c+ dendritic cells in gut mucosa of celiac disease after in vivo gluten challenge. PLoS One. 2012;7(3):e33556. doi: 10.1371/journal.pone.0033556. Epub 2012 Mar 16.</citation>
    <PMID>22438948</PMID>
  </reference>
  <reference>
    <citation>Jansson UH, Kristiansson B, Magnusson P, Larsson L, Albertsson-Wikland K, Bjarnason R. The decrease of IGF-I, IGF-binding protein-3 and bone alkaline phosphatase isoforms during gluten challenge correlates with small intestinal inflammation in children with coeliac disease. Eur J Endocrinol. 2001 Apr;144(4):417-23. doi: 10.1530/eje.0.1440417.</citation>
    <PMID>11275953</PMID>
  </reference>
  <reference>
    <citation>Greco L, D'Adamo G, Truscelli A, Parrilli G, Mayer M, Budillon G. Intestinal permeability after single dose gluten challenge in coeliac disease. Arch Dis Child. 1991 Jul;66(7):870-2. doi: 10.1136/adc.66.7.870.</citation>
    <PMID>1863103</PMID>
  </reference>
  <reference>
    <citation>Horvath K, Nagy L, Horn G, Simon K, Csiszar K, Bodanszky H. Intestinal mast cells and neutrophil chemotactic activity of serum following a single challenge with gluten in celiac children on a gluten-free diet. J Pediatr Gastroenterol Nutr. 1989 Oct;9(3):276-80. doi: 10.1097/00005176-198910000-00003.</citation>
    <PMID>2614612</PMID>
  </reference>
  <reference>
    <citation>Kontakou M, Przemioslo RT, Sturgess RP, Limb GA, Ellis HJ, Day P, Ciclitira PJ. Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge. Gut. 1995 Jul;37(1):52-7. doi: 10.1136/gut.37.1.52.</citation>
    <PMID>7672681</PMID>
  </reference>
  <reference>
    <citation>Strobel S, Busuttil A, Ferguson A. Human intestinal mucosal mast cells: expanded population in untreated coeliac disease. Gut. 1983 Mar;24(3):222-7. doi: 10.1136/gut.24.3.222.</citation>
    <PMID>6826106</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph A. Murray, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Randomized, double-blinded, placebo-controlled trial</keyword>
  <keyword>Oral food challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
    <mesh_term>Duodenal Diseases</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Wheat Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03288831
org study id: IRB 17-003596
nct id: NCT03288831
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This study evaluates why people with celiac disease and non-celiac gluten/wheat sensitivity
      develop rapid onset symptoms within hours of gluten exposure. Half of subjects will be given
      gluten and half will not.
When a person with celiac disease is exposed to gluten, their immune system attacks their
      bowel and causes abdominal pain, bloating, and diarrhea. This process takes 24-72 hours to
      occur. Some people without celiac disease develop similar symptoms when they eat gluten or
      wheat. Doctors and scientists do not know what causes this sensitivity to gluten. People with
      celiac disease and non-celiac gluten sensitivity report symptoms within hours of being
      exposed to gluten. This study evaluates why this occurs by looking at changes in blood,
      urine, stool, and the bowel after being given gluten.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Randomized, double-blinded, placebo-controlled oral gluten challenge
primary purpose: Other
masking: Triple (Participant, Care Provider, Investigator)
masking description: Subjects will be block randomized to either gluten-containing or placebo challenge.
measure: Activation of the Mucosal Innate Immune System after Oral Gluten Challenge
time frame: 4 hours
description: Small bowel biopsies will be assessed for markers of innate immune system activation: presence of granulocytes, granulocyte degranulation, products of degranulation, interleukins and cytokines involved in the innate immune system response, inflammatory mediators.
measure: Changes in Mucosal Permeability after Oral Gluten Challenge
time frame: Baseline and up to eight hours after gluten or placebo exposure
description: Mucosal permeability will be measure before and after oral gluten or placebo challenge with C13-mannitol lactulose urinary excretion testing. In addition, mucosal permeability will also be measured along the duodenum with a mucosal impedance probe.
measure: Detection of Gluten Peptides in Urine and Stool
time frame: Baseline and up to 72 hours after gluten or placebo exposure
description: Urine and stool samples will be assessed for the presence of gluten peptides. This will help assess how long these tests are positive after a known gluten exposure.
measure: Rapid Onset Symptom Development after Gluten Exposure
time frame: Baseline and up to 72 hours after gluten or placebo exposure
description: Subjects will record the symptoms they experience after gluten or placebo exposure. The will complete a simple symptom diary every 30 minutes for the first 2 hours.
arm group label: Normal Subjects, Gluten Drink
arm group type: Active Comparator
description: Normal subjects will drink a solution containing 6 grams of gluten one time.
arm group label: Normal Subjects, Placebo Drink
arm group type: Placebo Comparator
description: Normal subjects will drink a solution without gluten one time.
arm group label: Celiac Subjects, Gluten Drink
arm group type: Active Comparator
description: Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
arm group label: Celiac Subjects, Placebo Drink
arm group type: Placebo Comparator
description: Subjects with celiac disease will drink a solution without gluten one time.
arm group label: Gluten Sensitivity, Gluten Drink
arm group type: Active Comparator
description: Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
arm group label: Gluten Sensitivity, Placebo Drink
arm group type: Placebo Comparator
description: Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
intervention type: Dietary Supplement
intervention name: Gluten
description: Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
arm group label: Celiac Subjects, Gluten Drink
arm group label: Gluten Sensitivity, Gluten Drink
arm group label: Normal Subjects, Gluten Drink
intervention type: Dietary Supplement
intervention name: Placebo
description: Subjects will drink a mixture of rice water and Tang flavoring one time.
arm group label: Celiac Subjects, Placebo Drink
arm group label: Gluten Sensitivity, Placebo Drink
arm group label: Normal Subjects, Placebo Drink
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Joseph A. Murray, M.D.
role: Principal Investigator
affiliation: Mayo Clinic
facility: 
country: United States
url: https://www.mayo.edu/research/clinical-trials
description: Mayo Clinic Clinical Trials
citation: Leffler D, Schuppan D, Pallav K, Najarian R, Goldsmith JD, Hansen J, Kabbani T, Dennis M, Kelly CP. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. 2013 Jul;62(7):996-1004. doi: 10.1136/gutjnl-2012-302196. Epub 2012 May 22.
PMID: 22619366
citation: Adriaanse MP, Tack GJ, Passos VL, Damoiseaux JG, Schreurs MW, van Wijck K, Riedl RG, Masclee AA, Buurman WA, Mulder CJ, Vreugdenhil AC. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013 Feb;37(4):482-90. doi: 10.1111/apt.12194. Epub 2013 Jan 7.
PMID: 23289539
citation: Anderson RP, van Heel DA, Tye-Din JA, Barnardo M, Salio M, Jewell DP, Hill AV. T cells in peripheral blood after gluten challenge in coeliac disease. Gut. 2005 Sep;54(9):1217-23. doi: 10.1136/gut.2004.059998.
PMID: 16099789
citation: Camarca A, Radano G, Di Mase R, Terrone G, Maurano F, Auricchio S, Troncone R, Greco L, Gianfrani C. Short wheat challenge is a reproducible in-vivo assay to detect immune response to gluten. Clin Exp Immunol. 2012 Aug;169(2):129-36. doi: 10.1111/j.1365-2249.2012.04597.x.
PMID: 22774987
citation: Beitnes AC, Raki M, Brottveit M, Lundin KE, Jahnsen FL, Sollid LM. Rapid accumulation of CD14+CD11c+ dendritic cells in gut mucosa of celiac disease after in vivo gluten challenge. PLoS One. 2012;7(3):e33556. doi: 10.1371/journal.pone.0033556. Epub 2012 Mar 16.
PMID: 22438948
citation: Jansson UH, Kristiansson B, Magnusson P, Larsson L, Albertsson-Wikland K, Bjarnason R. The decrease of IGF-I, IGF-binding protein-3 and bone alkaline phosphatase isoforms during gluten challenge correlates with small intestinal inflammation in children with coeliac disease. Eur J Endocrinol. 2001 Apr;144(4):417-23. doi: 10.1530/eje.0.1440417.
PMID: 11275953
citation: Greco L, D'Adamo G, Truscelli A, Parrilli G, Mayer M, Budillon G. Intestinal permeability after single dose gluten challenge in coeliac disease. Arch Dis Child. 1991 Jul;66(7):870-2. doi: 10.1136/adc.66.7.870.
PMID: 1863103
citation: Horvath K, Nagy L, Horn G, Simon K, Csiszar K, Bodanszky H. Intestinal mast cells and neutrophil chemotactic activity of serum following a single challenge with gluten in celiac children on a gluten-free diet. J Pediatr Gastroenterol Nutr. 1989 Oct;9(3):276-80. doi: 10.1097/00005176-198910000-00003.
PMID: 2614612
citation: Kontakou M, Przemioslo RT, Sturgess RP, Limb GA, Ellis HJ, Day P, Ciclitira PJ. Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge. Gut. 1995 Jul;37(1):52-7. doi: 10.1136/gut.37.1.52.
PMID: 7672681
citation: Strobel S, Busuttil A, Ferguson A. Human intestinal mucosal mast cells: expanded population in untreated coeliac disease. Gut. 1983 Mar;24(3):222-7. doi: 10.1136/gut.24.3.222.
PMID: 6826106
responsible party type: Principal Investigator
investigator affiliation: Mayo Clinic
investigator full name: Joseph A. Murray, M.D.
investigator title: Professor of Medicine
mesh term: Celiac Disease
mesh term: Duodenal Diseases
mesh term: Hypersensitivity
mesh term: Wheat Hypersensitivity
sharing ipd: No